Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp

Share on StockTwits

Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp decreased its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 30.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,000 shares of the biopharmaceutical company’s stock after selling 12,400 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s holdings in Regeneron Pharmaceuticals were worth $11,717,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 4.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock valued at $1,085,000 after buying an additional 141 shares in the last quarter. Cito Capital Group LLC lifted its stake in Regeneron Pharmaceuticals by 4.3% in the 3rd quarter. Cito Capital Group LLC now owns 3,650 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 150 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 1.3% in the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,325 shares of the biopharmaceutical company’s stock valued at $4,252,000 after buying an additional 153 shares in the last quarter. HPM Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. HPM Partners LLC now owns 4,744 shares of the biopharmaceutical company’s stock worth $1,917,000 after purchasing an additional 157 shares during the period. Finally, Virtus ETF Advisers LLC lifted its stake in shares of Regeneron Pharmaceuticals by 7.2% during the 3rd quarter. Virtus ETF Advisers LLC now owns 2,480 shares of the biopharmaceutical company’s stock worth $1,002,000 after purchasing an additional 167 shares during the period. Institutional investors own 67.20% of the company’s stock.

Shares of Regeneron Pharmaceuticals stock traded up $0.57 during trading hours on Friday, hitting $408.63. 699,866 shares of the company’s stock traded hands, compared to its average volume of 850,080. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.04 and a quick ratio of 3.30. The company has a market capitalization of $43.24 billion, a PE ratio of 30.47, a P/E/G ratio of 1.72 and a beta of 1.14. Regeneron Pharmaceuticals Inc has a twelve month low of $281.89 and a twelve month high of $416.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, beating the consensus estimate of $4.94 by $0.93. The company had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The company’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the firm earned $3.99 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals Inc will post 18.88 earnings per share for the current fiscal year.

In other news, VP Christopher R. Fenimore sold 1,848 shares of the stock in a transaction dated Thursday, December 20th. The shares were sold at an average price of $358.97, for a total transaction of $663,376.56. Following the transaction, the vice president now owns 9,871 shares of the company’s stock, valued at $3,543,392.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph L. Goldstein sold 1,791 shares of the stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $5,786,740. The disclosure for this sale can be found here. Insiders have sold 3,645 shares of company stock valued at $1,399,980 over the last 90 days. Insiders own 12.42% of the company’s stock.

A number of brokerages have weighed in on REGN. BidaskClub raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday. Cowen reaffirmed a “hold” rating and issued a $385.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday. TheStreet lowered Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Tuesday, November 13th. Argus reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 13th. Finally, ValuEngine raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 15th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $404.11.

TRADEMARK VIOLATION WARNING: This report was originally published by Fairfield Current and is owned by of Fairfield Current. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.fairfieldcurrent.com/news/2019/01/11/her-majesty-the-queen-in-right-of-the-province-of-alberta-as-represented-by-alberta-investment-management-corp-decreases-position-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Balanced Fund

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply